Changing Incidence and Survival in Patients with AIDS-Related Non-Hodgkin's Lymphomas in the Era of Highly Active Antiretroviral Therapy (HAART)

References

• Goedert J. J., Coté T. R., Virgo P., Scoppa S. M., Kingma D. W., Gail M. H., Jaffe E. S., Biggar R. J., AIDS-Cancer Match Study Group. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351: 1833–39
   PubMed Web of Science ®Google Scholar
• Beral V., Peterman T., Berkelman R., Jaffe H. AIDS-associated non-Hodgkin's lymphoma. Lancet 1991; 337: 805–9
   PubMed Web of Science ®Google Scholar
• Harnly M. E., Swan S. H., Holly E. A., Kelter A., Padian N. Temporal trends in the incidence of non-Hodgkin's lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS). Am. J. Epidemiol 1988; 128: 261–67
   PubMed Web of Science ®Google Scholar
• Serraino D., Salamina G., Fanceschi S., Dubois D., La Vecchia C., Brunei J. B., Ancelle-Park R. A. The epidemiology of AIDS-associated non-Hodgkin's lymphoma in the World Health Organization European Region. Br. J. Cancer 1992; 66: 912–16
   PubMed Web of Science ®Google Scholar
• Rabkin C. S., Goedert J. J. Risk of non-Hodgkin's lymphoma and Kaposi's sarcoma in homosexual men. Lancet 1990; 2: 248–49
   Web of Science ®Google Scholar
• Obrams G. I., Grufferman S. Epidemiology of HIV-associated non-Hodgkin's lymphoma. Cancer. Surv 1991; 10: 91–102
   PubMedGoogle Scholar
• Klencke B., Kaplan L. Advances and future challenges in non-Hodgkin's lymphomas. Curr. Opin. Oncol 1998; 10: 422–27
   PubMedGoogle Scholar
• Straus D. J. HIV-related lymphomas. Curr. Opin. Oncol 1997; 9: 450–54
   PubMedGoogle Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Jr., Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med 1993; 328: 1002–6
   PubMed Web of Science ®Google Scholar
• Gordon L. I., Harrington D., Andersen J., Colgan J., Glick J., Neiman R., Mann R., Resnick G. D., Barcos M., Gottlieb A., et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N. Engl. J. Med 1992; 327: 1342–49
   PubMed Web of Science ®Google Scholar
• Cooper I. A., Wolf M. M., Robertson T. I., Fox R. M., Matthews J. P., Stone J. M., Ding J. C., Dart G., Matthews J., Firkin F. C., Lowenthal R. M., Ironside P., Australian and New Zealand Lymphoma Group. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. J. Clin. Oncol 1994; 12: 769–78
   PubMed Web of Science ®Google Scholar
• Kaplan L. D., Straus D. J., Testa M. A., Von Roenn J., Dezube B. J., Cooley T. P., Herndier B., Northfelt D. W., Huang J., Tulpule A., Levine A. M., for the Nationale Institute of Allergy and Infectious Diseases AIDS Clinical Trial Group. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N. Engl. J. Med 1997; 336: 1641–48
   PubMed Web of Science ®Google Scholar
• Tan B., Ratner L. The use of new antiretroviral therapy in combination with chemotherapy. Curr. Opin. Oncol 1997; 9: 455–64
   PubMedGoogle Scholar
• Pluda J. M., Yarchoan R., Jaffe E. S., Feuerstein I. M., Solomon D., Steinberg S. M., Wyvill K. M., Raubitschek A., Katz D., Broder S. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann. Intern. Med 1990; 113: 276–82
   PubMed Web of Science ®Google Scholar
• Grulich A. E. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy. J. Acquire. Immune. Defic. Syndr 1999; 21(Suppl. 1)27–30
   Google Scholar
• Jacobson L. P., Yamashita T. E., Detels R., Margolick J. B., Chmiel J. S., Kingsley L. A., Melnick S., Munoz A., Multicenter AIDS Cohort Study. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J. Acquire. Immune. Defic. Syndr 1999; 21(Suppl. 1)34–41
   Google Scholar
• Rabkin C. S., Testa M. A., Huang J., Von Roenn J. H. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS clinical trial group study participants. J. Acquire. Immune. Defic Syndr 1999; 21(Suppl. 1)31–33
   PubMed Web of Science ®Google Scholar
• Buchbinder S. P., Holmberg S. D., Scheer S., Colfax O., O'Malley P., Vittinghoff E. Combination antiretroviral therapy and incidence of AIDS-related malignancies. J. Acquire. Immune. Defic. Syndr 1999; 21(Suppl. 1)23–26
   PubMedGoogle Scholar
• Brodt H. R., Kamps B. S., Gute P., Knupp B., Staszewski S., Helm E. B. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11: 1731–38
   PubMed Web of Science ®Google Scholar
• Palella F. J., Jr, Delaney K. M., Moorman A. C., Loveless M. O., Fuhrer J., Satten G. A., Aschman D. J., Holmberg S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med 1998; 338: 853–60
   PubMed Web of Science ®Google Scholar
• Bower M., Fife K., Sullivan A., Kirk S., Philips R. H., Nelson M., Gazzard B. G. Treatment and outcome in presumed and confirmed AIDS-related primary cerebral lymphoma. Eur. J. Cancer 1999; 35: 601–4
   PubMed Web of Science ®Google Scholar
• Brodt H. R., Kamps B. S., Helm E. B., Schofer H., Mitrou P. S. Kaposi's sarcoma in HIV infection: impact on opportunistic infections and survival. AIDS 1998; 20: 1475–81
   Web of Science ®Google Scholar
• Ledergerber B., Telenti A., Egger M., Swiss HIV Cohort Study. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Br. Med. J 1999; 319: 23–4
   PubMed Web of Science ®Google Scholar
• Corn B. W., Marcus S. M., Topham A., Hauck W., Curran W. J., Jr. Will the primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?. Cancer 1997; 79: 2409–13
   PubMed Web of Science ®Google Scholar
• Raez L. E., Patel P., Feun L., Restrepo A., Raub W. A., Jr, Cassileth P. A. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit. Rev. Oncog 1998; 9: 199–208
   PubMed Web of Science ®Google Scholar
• Levine A. M. Non-Hodgkin's lymphomas and other malignancies in the acquired immune deficiency syndrome. Semin. Oncol 1987; 14: 34–9
   PubMed Web of Science ®Google Scholar
• MacMahon E. M., Glass J. D., Hayward S. D., Mann R. B., Becker P. S., Charache P., McArthur J. C., Ambinder R. F. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991; 338: 969–73
   PubMed Web of Science ®Google Scholar
• IARC working group on the evaluation of carcinogenic risks to humans: human immundeficiency viruses and human T cell lymphotropic viruses IARC Monogr Eval. Carcinog. Risks. Hum 1996; 67: 1–424
   PubMedGoogle Scholar
• Przybylski G. K., Goldman J., Ng V. L., McGrath M. S., Herndier B. G., Schenkhein D. P., Monroe J. G., Silberstein L. E. Evidence for early B-cell activation preceding the development or Epstein-Barr virus-negative acquired immunodeficiency syndrome-related lymphoma. Blood 1996; 88: 4620–29
   PubMed Web of Science ®Google Scholar
• Biemer J. J. Malignant lymphomas associated with immunodeficiency states. Ann. Clin. Lab. Sci 1990; 20: 175–91
   PubMed Web of Science ®Google Scholar
• Ridolfo A. L., Santambrogio S., Mainini F., Vago L., Gervasoni C., Gori A., Parravicini C., d'Arminio Monforte A., Galli M. High frequency of non-Hodgkin's lymphoma in patients with HIV-associated Kaposi's sarcoma. AIDS 1996; 10: 181–85
   PubMed Web of Science ®Google Scholar
• Aboulafia D. Epidemiology and pathogenesis of AIDS-related lymphomas. Oncology (Huntingt.) 1998; 12: 1068–81
   PubMed Web of Science ®Google Scholar
• Vaccer E., Tirelli U., Spina M., Talamini R., Errante D., Simonelli C., Carbone A. Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: A single-institute study of 96 patients. J Clin Oncol 1996; 14: 2217–23
   PubMed Web of Science ®Google Scholar
• Grulich A. E., Wan X., Law M. G., Milliken S. T., Lewis C. R., Garsia R. J., Gold J., Finlayson R. J., Cooper D. A., Kaldor J. M. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000; 14: 133–40
   PubMed Web of Science ®Google Scholar
• Tirelli U., Franceschi S., Carbone A. Malignant tumours in patients with HIV-infection. Br. Med. J 1994; 308: 1148–53
   PubMed Web of Science ®Google Scholar
• Kersten M. J., Verduyn T. J., Reiss P., Evers L. M., de Wolf F., van Oers M. H. Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: clinical outcome and effect on HIV-1 viral load. Ann Oncol 1998; 9: 1135–38
   PubMed Web of Science ®Google Scholar
• Weiss R., Huhn D., Mitrou P., Nerl C., Schumann D., Scheidegger C., Knauf W., Trenn G., Kronawitter U., VanLunzen J., Arasteh K., Herbst H. HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy. Leuk. Lymphoma 1998; 29: 103–18
   PubMed Web of Science ®Google Scholar
• Straus D. J., Huang J., Testa M. A., Levine A. M., Kaplan L. D., National Institute of Allergy and Infectious diseases AIDS Clinical Trials Group. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS clinical trials group protocol 142-low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol 1998; 16: 3601–6
   PubMed Web of Science ®Google Scholar
• Campbell P., Iland H., Gibson J., Joshua D. Syngeneic stem cell transplantation for HIV-related lymphoma. Br. J. Haematol 1999; 105: 795–8
   PubMed Web of Science ®Google Scholar
• Blay J. Y., Conroy T., Chevreau C., Thyss A., Quesnel N., Houchingue E., Bouabdallah R., Coiffier B., Wagner J. P., Le Mevel A., Dramais-Marcel D., Baumelou E., Chauvin F., Biron P. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J. Clin. Oncol 1998; 16: 864–71
   PubMed Web of Science ®Google Scholar
• Reni M., Ferreri A. J., Garancini M. P., Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann. Oncol 1997; 8: 227–34
   PubMed Web of Science ®Google Scholar
• Thiessard F., Morlat P., Marimoutou C., Labouyrie E., Ragnaud J. M., Pellegrin J. L., Dupon M., Dabis F., Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Prognostic factors after non-Hodgkin's lymphoma in patients infected with the human immunodficiency virus. Aquitaine Cohort, France, 1986–1997. Cancer 2000; 88: 1696–1702
   PubMed Web of Science ®Google Scholar